A hormone’s guide to healthy living
Research in the 20th century showed us the ill effects of our lifestyle choices. Countless studies demonstrated that smoking and drinking were gateways to cancer and other diseases. Scientists now are finding that the modern-day way of life — a sedentary lifestyle and a high-calorie diet — can have equally disastrous health impacts. The constant obsession with screen time has affected our metabolism in a way that makes us more susceptible to developing insulin resistance, thereby leading to Type 2 diabetes.
On the other hand, the human body can synthesize molecules that keep our metabolism in check and prevent it from going awry. These molecules, called adipokines, are hormones secreted by fat cells (and other metabolic organs in the body) and serve as the body’s defense mechanism against metabolic anomalies.
A team of researchers in Philipp Scherer and Wen-hong Li’s labs at the University of Texas Southwestern Medical Center takes a special interest in the physiological effects of adipokines. Toshiharu Onodera, a postdoctoral fellow, said, “We have had a longstanding interest in pancreatic islets with respect to the relationship between adiponectin and the health and functionality of insulin-producing cells because there is a substantial presence of adiponectin receptors in pancreatic beta cells.”
In a study published recently in the Journal of Lipid Research, Onodera, Ebrahim Zadeh and their team evaluated the effects of a modified version of an adipokine, adiponectin, on glucose and lipid metabolism.

“Adiponectin is a multifaceted protein with beneficial effects on many organs, such as the liver, pancreas, muscles, heart and kidneys,” Onodera said. “These effects are mediated by adiponectin receptors.”
While different ligands (also called adipokine agonists) can activate adiponectin receptors, none of them are clinically useful. One such agonist, AdipoRon, is limited further by its poor solubility and bioavailability.
“In our study,” Onodera said, “we expand on the protective effects of AdipoRon by generating a series of AdipoRon analogs containing amphiphilic ethylene glycol chains.”
In studies of mice that were genetically altered to have low insulin and fed a high-fat diet, the researchers found that their bodies absorbed one of these analogs, AdipoRonPEG5, better than the others, and it effectively reduced toxic lipid species in organs, resulting in dramatically improved therapeutic effect on diabetes and fatty liver disease. After administration of AdipoRonPEG5, the mice had improved blood glucose levels, decreased lipotoxicity in the pancreas, reduced fibrosis in adipose tissue and reduced gluconeogenesis in the liver.
“We believe that we made substantial progress towards the improvement of an existing molecule of importance for diabetes and fatty liver disease,” Onodera said.
Although AdipoRonPEG5 has longer half-life in circulation than its un-PEGylated form, the team was concerned about its frequent dosage, so they administered the agonist to mice twice a day for five days to observe a protective effect. “The next step is to generate longer-acting versions of these adiponectin receptor agonists,” Onodera said.
These findings could present a novel mechanism for the design of diabetes-combating drugs.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

How signals shape DNA via gene regulation
A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent MCP paper.

A game changer in cancer kinase target profiling
A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent MCP paper.

How scientists identified a new neuromuscular disease
NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.

Unraveling cancer’s spaghetti proteins
MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting “undruggable” molecules.

How HCMV hijacks host cells — and beyond
Ileana Cristea, an ASBMB Breakthroughs webinar speaker, presented her research on how viruses reprogram cell structure and metabolism to enhance infection and how these mechanisms might link viral infections to cancer and other diseases.

Understanding the lipid link to gene expression in the nucleus
Ray Blind, an ASBMB Breakthroughs speaker, presented his research on how lipids and sugars in the cell nucleus are involved in signaling and gene expression and how these pathways could be targeted to identify therapeutics for diseases like cancer.